Cemiplimab Plus Gemcitabine

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Pancreatic Ductal Adenocarcinoma (mPDAC)

Drug Information

Target Indication

Pancreatic Ductal Adenocarcinoma (mPDAC)

Clinical Trial

Last updated: 8/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Related Pipeline

Homozygous Familial Hypercholesterolemia

Hypercholesterolemia

Neovascular Age-Related Macular Degeneration

Non-Small Cell Lung Cancer

Allergic Conjunctivitis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts